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Purpose: To investigate the clinical and cost effectiveness of switching real-life asthma 
patients from other types of inhalers to the Easyhaler® (EH) for the administration of inhaled 
corticosteroids (ICS).
Patients and methods: Historical, matched-cohort study of 1,958 asthma patients  (children 
and adults) treated in UK primary-care practices, using data obtained from the Optimum 
Patient Care Research Database and Clinical Practice Research Datalink. Other inhalers (OH) 
included pressurized metered-dose inhalers, breath-actuated inhalers, and dry-powder inhalers, 
delivering beclomethasone, budesonide, fluticasone, or ciclesonide. Patients remaining on OH 
unchanged (same drug, dosage, and device; n=979) were matched 1:1 with those switched to 
the EH (beclomethasone or budesonide) at the same or lower ICS dosage (n=979), based on 
age, sex, year of index patient review/switch, most recent ICS drug, dosage, and device, and 
the number of severe exacerbations and average daily short-acting β
2
 agonist (SABA) dosage 
in the preceding year. Clinical outcomes and health care costs were compared between groups 
for 12 months before and after the switch. Co-primary clinical outcomes were: 1) risk domain 
asthma control (RDAC) – no asthma-related hospitalization, acute oral steroid use, or lower 
respiratory tract infection (LRTI); 2) exacerbation rate (American Thoracic Society [ATS] 
definition) – where exacerbation is asthma-related hospitalization or acute oral steroid use; 
3) exacerbation rate (clinical definition) – where exacerbation is ATS exacerbation or LRTI; and 
4) overall asthma control (OAC) – RDAC plus average salbutamol-equivalent SABA dosage 
#200 µg/day. Non-inferiority (at least equivalence) of EH was tested against OH for the four 
co-primary outcomes in order (hierarchical approach) by comparing the difference in propor-
tions of patients [EH-OH] achieving asthma control or having no exacerbations in the outcome 
year, using a limit of 10% difference.
Results: Non-inferiority was shown for the EH for all four co-primary outcomes. There were 
no significant differences between groups for RDAC or exacerbation rates, but EH patients 
were  significantly more likely to achieve OAC (adjusted odds ratio [95% confidence interval]: 
1.26 [1.05, 1.52]), as significantly more EH than OH patients had an average SABA dosage 
of #200 µg/day (52% versus 47%, respectively; P,0.001). Mean asthma-related health care costs 
increased from baseline to outcome years in both groups, but SABA costs increased significantly 
more in OH than EH patients (mean difference £5.5/patient/year) and consultation costs decreased 
significantly more in EH than OH patients (mean difference £13.5/patient/year).
Conclusion: Typical asthma patients may be switched from other ICS devices to the Easyhaler® 
with no reduction in clinical effectiveness or increase in cost.
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Introduction
The Easyhaler® (EH; Orion Pharma UK Ltd, Newbury, 
Berkshire, England) is a dry-powder inhaler (DPI) that may 
be prescribed for the treatment of asthma.1 In experimental 
studies and randomized controlled clinical trials, the EH has 
been shown to be at least equivalent in lung deposition and/
or clinical efficacy to other DPIs or pressurized metered-
dose inhalers (pMDI) for a variety of asthma medications, 
including inhaled corticosteroids (ICS),2–10 short-acting β
2
 
receptor agonists (SABA),11–18 and long-acting β
2
 receptor 
agonists (LABA).19
In the UK, the EH is available for the delivery of beclom-
ethasone, budesonide, formoterol, or salbutamol.1 Physicians 
may choose the EH over another type of inhaler for a number 
of reasons. First, unlike some other DPIs in common use, 
which require inspiratory flow rates of 45–60 L/minute 
for optimal drug delivery,20–23 the EH generates a consis-
tent therapeutic dose at inspiratory flow rates as low as 
28 L/minute.12,23,24 Even young children with asthma11,12 and 
elderly patients with chronic obstructive pulmonary disease 
(COPD)25 can usually manage inspiratory flow rates of at 
least 28 L/minute.
Second, the EH generates a consistent emitted dose and 
fine-particle fraction across a range of inspiratory flow rates 
from 30 to 90 L/minute, in contrast to a widely used DPI 
which showed greater variability in emitted dose at any flow 
rate and a fine-particle dose that was flow-rate dependent.23,26 
Thus, the patient is more likely to receive the same dose of 
drug every time with the EH, even at low or variable inspira-
tory flow rates.
Third, patient satisfaction generally is better with the 
EH than with other inhalers. In numerous studies compar-
ing the EH with other inhalers, most people with asthma or 
parents of children with asthma expressed a preference for 
the EH.2–6,27 In a meta-analysis of nine clinical trials, the 
EH was clearly preferred over the pMDIs and other DPIs 
evaluated. In particular, the EH was favored by patients for 
its ease of use, learning how to use, dosing, and inhaling 
through the device.28 One of the features for which the EH 
repeatedly fared better among patients was the perception of 
drug inhalation, or receiving the powder from the device and 
thus controlling inhalation of the powder.27,29
A fourth consideration is that the EH is less expensive 
than most other DPIs. Thus, there are several potential 
advantages to switching asthma patients on ICS therapy 
from another type of inhaler to the EH. However, the clini-
cal effectiveness of such a switch has not been investigated 
in a large and diverse population of asthma patients, ie, in 
real-life asthma care – where critical inhalation errors are 
both common and various.20,21,29–34
Critical inhalation errors are defined as any error in the 
handling or use of the inhaler that is likely to significantly 
impair the delivery of adequate medication, and they have 
been documented for all inhaler types.30 Because they 
reduce the delivered dose of medication, critical errors 
compromise asthma control and thus increase the costs of 
asthma  management.30 As demonstration of correct inhaler 
technique is typically a prerequisite for inclusion in controlled 
clinical trials evaluating the efficacy of inhaled medications 
or comparing different inhalers,20,31,35,36 the applicability of 
such trials to asthma patients in real life is limited. In fact, it 
has been observed that typical asthma patients make many 
errors – even with their regular inhaler – which may negate 
the benefits documented in controlled clinical trials.30–33
The technical differences among the various ICS devices, 
even within the same class of device (such as DPIs), are 
sufficient that a switch from one type of inhaler to another 
increases the potential for critical handling or inhalation 
errors.22,29,31,34 Switching a patient from one inhaler to 
another without an accompanying face-to-face consultation 
may further compromise asthma control,37,38 yet switching 
by electronic review or correspondence occurs with some 
frequency in clinical practice.
Hence, we investigated the results of switching from any 
other inhaler to the EH for the delivery of ICS therapy in a 
large and diverse population of asthma patients (children 
and adults) in UK primary-care practice. We focused the 
comparisons on the inhaler devices by limiting the study to 
asthma patients who were relatively stable on their current 
ICS therapy. Our hypothesis was that switching these patients 
from another type of inhaler to the EH in a real-life setting 
would nevertheless result in a significant reduction in clinical 
effectiveness and thus a significant increase in the costs of 
on-going asthma therapy.
Material and methods
study design and patients
We conducted an historical, matched-cohort study of asthma 
patients in the UK treated in primary-care practice and pre-
scribed ICS therapy. We obtained the patient data from two 
large, anonymized UK primary-care databases: the Optimum 
Patient Care Research Database (OPCRD)39 and the Clinical 
Practice Research Datalink (CPRD),40 formerly called the 
General Practice Research Database (GPRD). Both databases 
were examined for suitable patients spanning the period from 
January 2005 to December 2012. We took care to avoid 
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Baseline
Index prescription date:
OH (n=1,958)
EH (n=979)
OH (n=979)
Patients either switched to
EH at same or lower ICS
dosage or remained on OH
unchanged (same ICS
drug, dosage, and device).
Patients matched 1:1.
1 year
(for patient characterization)
1 year
(for clinical and cost comparisons)
Outcome
Figure 1 schematic of the study design.
Notes: easyhaler® (Orion Pharma UK ltd, newbury, Berkshire, england).
Abbreviations: eh, easyhaler®; ics, inhaled corticosteroid; Oh, other inhaler.
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duplication of individual patients by cross-referencing the 
databases using patient characteristics.
Qualifying patients comprised two groups: 1) those 
remaining on any other inhaler (OH) than the EH for the 
duration of the investigation period; and 2) those who were 
switched from an OH to the EH. For each patient, we studied 
the medical records for two consecutive years: a baseline year 
preceding the index prescription date (IPD) on which the 
physician either continued the patient on an OH or switched 
the patient to the EH, and an outcome year following the 
IPD (Figure 1).
In order to ensure that the OH group was limited to 
patients whose physician clearly intended to continue the 
patient on the current ICS therapy unchanged, the OH group 
was restricted to patients who, at IPD, remained on the same 
drug, dosage, and device as their most recent prescription. 
But in order to ensure as large a study group as possible, 
we placed no such restrictions on the much smaller pool of 
potential EH patients, who were permitted a change of ICS 
drug (to beclomethasone or budesonide) and a decrease in 
ICS dosage, in addition to the change of device (from OH 
to EH) at IPD. The study population included smokers and 
ex-smokers in addition to nonsmokers and patients whose 
smoking status was not recorded. However, patients were 
excluded if they were prescribed a fixed-dose combination 
inhaler during their baseline year, they had more than one 
ICS switch at IPD, or they did not have complete data for 
both the baseline and outcome years.
To ensure that we were comparing the two treatments in 
similar patients, we matched the patients remaining on an 
OH with those switched to the EH in a ratio of 1:1, based 
on several demographic and clinical characteristics: age, 
sex, year of IPD, most recent ICS prescription (drug, dos-
age, and device), and the number of severe exacerbations 
and average daily SABA dosage during the baseline year 
(Table 1). Thus, within the demographic categories, EH 
and OH patients were matched on the drugs and dosages 
required to achieve comparable asthma control during their 
baseline year.
clinical outcomes
As definitions of asthma control and acute exacerbation dif-
fer among organizations and studies, we examined several 
clinical outcome measures, encompassing various combi-
nations of asthma-related hospital attendance, use of acute 
oral steroids, general practitioner (GP) consultations for 
lower respiratory tract infections (LRTI) requiring antibiotic 
therapy, average daily SABA usage, and changes in asthma 
therapy, in addition to controller–reliever ratios during the 
year of interest. In all, eight simple or composite measures 
of clinical effectiveness were compared between treatment 
groups: four co-primary outcomes (Table 2) and four second-
ary outcomes (Table 3). For the purpose of investigating the 
non-inferiority (clinical equivalence) of EH against OH, the 
four co-primary outcomes were analyzed using a four-tier 
hierarchical approach, as described in the statistical analysis 
section.
health economic outcomes
We examined asthma treatment costs in both groups for the 
baseline and outcome years. Total asthma-related health 
care costs were calculated from the costs of asthma drugs, 
primary-care asthma consultations, and respiratory-related 
hospital attendance/admission. Drug costs included ICS, oral 
corticosteroids for acute use, SABA, LABA, leukotriene 
receptor antagonists (LTRA), theophylline, antibiotics pre-
scribed for LRTI, and other respiratory drugs.
Quantities of resources used were obtained from the 
patient databases and multiplied by unit costs to produce 
total costs. Unit costs for asthma drugs were obtained from 
the Prescription Service of the National Health Service 
(NHS) Business Services Authority via the Dictionary of 
Medicines and Devices.41 Drug unit prices were converted 
to 2010 prices for statistical analysis. Unit costs for GP 
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Table 2 co-primary measures of clinical effectiveness
Outcome Definition
1.  risk domain  
asthma control;  
controlled or  
uncontrolled
controlled if:
•   no asthma-related hospital 
attendance/admission,a
•   no gP consultations for lrTi,b and
•   no prescriptions for acute oral 
steroid courses
2.  exacerbation rate  
(ATS/ERS definition); 
number of exacerbations
Where exacerbation is an occurrence of:
•   Asthma-related hospital attendance/
admissiona or
•   Use of acute oral steroids
3.  exacerbation rate  
(clinical definition);  
number of exacerbations
Where exacerbation is an occurrence of:
•   Asthma-related hospital attendance/
admission,a
•   gP consult for lrTi,b or
•   Use of acute oral steroids
4.  Overall asthma control; 
controlled or  
uncontrolled
controlled if:
•   risk domain asthma control, plus
•   Average prescribed sABA  
dosage #200 µg/day for salbutamol  
or #500 µg/day for terbutaline
Notes: aAsthma-related hospital attendance/admission included Accident and 
emergency, out-of-hours, and outpatient departments; bconsultations for lower 
respiratory tract infections requiring antibiotic therapy.
Abbreviations: ATs/ers, American Thoracic society/european respiratory 
society; gP, general practitioner; lrTi, lower respiratory tract infection; sABA, 
short-acting β2 receptor agonist.
Table 1 Matching criteria
Age at iPD
 #16 years exact match
 .16 years ±5 years
sex Male/female
Year of iPD ±3 years
Most recent ics scripta Drug, dosage, and device
severe exacerbationsb 0, 1, or 2+ in baseline year
sABA usage, average daily dose 0, 1–200, 201–400, 401+ µgc 
in baseline year
Notes: aPatients were matched on their most recent ics prescription (drug, dosage, 
and device) prior to iPD; bATS/ERS definition; csalbutamol-equivalent dosages.
Abbreviations: ATs/ers, American Thoracic society/european respiratory 
society; ics, inhaled corticosteroid; iPD, index prescription date; sABA, short-
acting β2 receptor agonist.
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consultations were derived from the Personal Social Ser-
vices Research Unit report: Unit Costs of Health and Social 
Care 2011,42 assuming an average consultation duration of 
11.7 minutes. Hospital usage costs were obtained from the 
NHS Reference Costs 2010–2011.43
statistical analysis
We carried out all analyses using SPSS Statistics version 20 
(IBM Corporation, Armonk, NY, USA), SAS version 9.3 
(SAS Institute Inc., Cary, NC, USA), and Microsoft Excel 
2007 (Microsoft Corporation, Redmond, WA, USA). We 
Table 3 secondary measures of clinical effectiveness
Outcome Definition
Treatment stability  
(definition 1);
stable or unstable
stable if:
•   no asthma-related hospital attendance/
admission,a
•   no gP consultations for lrTi,b
•   no prescriptions for acute oral steroids, and
•   no change in therapy ($50% increase in 
ics dosage, change in ics drug or delivery 
device, and/or additional therapy with 
theophylline or lTrA)
Treatment stability  
(definition 2);
stable or unstable
stable if:
•   no asthma-related hospital attendance/
admission,a
•   no gP consultations for lrTi,b
•   no prescriptions for acute oral steroids, and
•   no change in therapy ($50% increase in 
ics dosage and/or additional therapy with 
theophylline or lTrA)
sABA dosage Average daily dose (µg)
controller–reliever  
ratioc
categorized: ,0.5 or $0.5
Notes: aAsthma-related hospital attendance/admission included Accident and 
emergency, out-of-hours, and outpatient departments; bconsultations for lower 
respiratory tract infections requiring antibiotic therapy; ccalculated as [number of 
units of controllers/(units of controllers + relievers)].
Abbreviations: gP, general practitioner; ics, inhaled corticosteroid; lrTi, lower 
respiratory tract infection; lTrA, leukotriene receptor antagonist; sABA, short-
acting β2 receptor agonist.
defined statistically significant results as P,0.05, and trends 
as P$0.05 but ,0.10. We report mean values with their 
standard deviations (SD), median values with their inter-
quartile ranges (IQR; percentiles 25 and 75), and adjusted 
odds/rate ratios and differences in proportions with their 
95% confidence intervals (CI). Dosages for SABA drugs 
are reported as salbutamol-equivalents and dosages for ICS 
drugs are reported as beclomethasone dipropionate (BDP)-
equivalents.
First, we conducted exploratory data analysis for all 
variables of interest, for both the baseline and outcome 
years. As a conservative approach, we considered differ-
ences between treatment groups as possibly important if 
P,0.10. We examined variables meeting this criterion for 
co-linearity and clinical importance to select those used as 
potential confounders (Figure S1) in the regression model-
ing of outcomes.
Next, we performed multivariate analyses using the full 
data set and each data split to identify baseline variables that 
are predictive (P,0.05) of each outcome variable during 
the outcome year. These baseline variables were considered 
as potential confounders in the regression modeling of out-
comes. Spearman correlation coefficients were calculated 
among all potential confounders to determine strengths of 
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 linear relationships between variables.  Correlation coef-
ficients were considered, in conjunction with clinical inter-
pretation, to identify pairings of variables that may present 
co-linearity issues at the modeling stage. We then used scat-
ter plots and error-bar plots to further investigate nonlinear 
relationships. When unadjusted and adjusted results were 
subsequently compared, no disparities were found in the 
direction of any differences between treatment groups before 
and after adjusting for confounders.
clinical outcomes
non-inferiority analysis
Our primary goal was to determine whether the EH is 
clinically non-inferior (at least equivalent) to the OH in this 
diverse patient population. To that end, we used a four-tier 
hierarchical approach for analysis of the co-primary clinical 
effectiveness measures. The four co-primary outcomes were 
assessed in pre-determined order, as presented in Table 2, 
using pre-specified acceptance limits. In order to claim non-
inferiority for an outcome on a lower level, it must first be 
demonstrated for the preceding outcome(s) in the hierarchy. 
If any outcome failed to meet the pre-specified limit, then 
any subsequent primary outcome(s) would be changed to a 
secondary outcome, which we analyzed singly.
The pre-specified acceptance limit was the demonstra-
tion of non-inferiority of the EH compared with the OH as 
 follows: a) for the measures of asthma control, the differ-
ence in the proportions of patients (EH − OH) achieving 
asthma control has a lower 95% CI of $−10%; and b) for the 
exacerbation rates, the difference in proportions of patients 
having no exacerbations has an upper 95% CI of #10%. 
Subsequent power calculations using an equivalence model 
confirmed that, with group numbers of 979 each, there was 
sufficient power (99%) to detect a 10% difference in propor-
tions between EH and OH.
Odds/rate ratios and other summary statistics
We compared the adjusted odds of achieving risk domain 
asthma control between matched treatment groups using 
conditional binary logistic regression models. Asthma control 
status (controlled/uncontrolled) was used as the dependent 
variable, with treatment and potential confounding factors 
as explanatory variables. The exacerbation rates (both defi-
nitions) were compared between treatment groups using a 
conditional Poisson regression model to obtain an estimate 
of relative exacerbation rates. The model used empirical 
standard errors (for more conservative CI estimations) and 
adjustments were made for potential baseline confounders. 
We compared the adjusted odds of achieving overall asthma 
control between matched treatment groups using conditional 
binary logistic regression models, as described above for risk 
domain asthma control.
For the secondary outcomes, we compared the adjusted 
odds of achieving treatment stability (both definitions) 
between matched treatment groups using conditional binary 
logistic regression models. Treatment stability status (stable/
unstable) was used as the dependent variable, with treatment 
and potential confounding factors as explanatory variables. 
The adjusted odds of being in a higher SABA usage category 
were compared between matched treatment groups using 
conditional ordinal logistic regression models. The SABA 
category (Table 1) was used as the dependent variable, with 
treatment and potential confounding factors as explanatory 
variables.
In addition, we compiled summary statistics for the 
controller–reliever ratio by treatment group. The controller–
reliever ratio was categorized (,0.5 and $0.5), and patient 
numbers and percentages determined for each category. 
Unadjusted conditional logistic regression (stratified by 
matching) was used to generate P-values for both the sum-
mary and categorized data.
health economic outcomes
After calculating total asthma-related health care costs, 
asthma drug costs, consultation costs, and hospitalization 
costs for each treatment group for the baseline and outcome 
years, we compared summary costs between matched treat-
ment groups using conditional logistic regression. These 
analyses were repeated for changes in costs between baseline 
and outcome years for each treatment group.
Results
Patients and devices
Of the 3,706,575 patients initially identified who had repeat 
prescriptions for an ICS, 1,029 were switched from an OH 
to the EH at the same or lower ICS dosage. After 1:1 match-
ing, 979 patients remained in the EH group and 979 uniquely 
matched patients were in the OH group. Of this total, 281 OH 
patients (28.7%) and 643 EH patients (65.7%) had a face-
to-face consultation at IPD; the remaining 698 OH patients 
(71.3%) and 336 EH patients (34.3%) had just an electronic 
review at IPD.
The baseline characteristics of both patient groups are 
summarized in Tables S1 and S2. Despite patient matching, 
some statistically significant differences remained. More 
EH than OH patients had significant co-morbidities, as 
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expressed by a Charlson co-morbidity index (CCI)44 score 
.0 (51.5% and 41%, respectively; Table S1), but there 
were no significant differences between treatment groups 
in the incidence of gastroesophageal reflux disease, cardiac 
disease, or ischemic heart disease (data not shown). The 
incidence of rhinitis was higher in OH than EH patients 
(30% and 24%, respectively; Table S1), but as CCI score and 
rhinitis were included as confounding factors (Figure S1), 
these baseline rates and differences were accounted for in 
the outcome analyses.
More importantly, patients in the EH group had fewer ICS 
prescriptions and inhalers, lower average daily ICS dosages, 
and lower controller–reliever ratios, but more asthma-related 
consultations with their primary-care physicians and a higher 
rate of asthma-related hospital outpatient department atten-
dance than patients in the OH group. There were no signifi-
cant differences in SABA prescriptions or daily SABA usage 
between groups, but LABA usage was significantly lower 
in the EH than the OH group. Given that there were no sig-
nificant differences between treatment groups for any of the 
four co-primary clinical effectiveness measures (Table S2), 
these findings suggest different patterns of self-management 
between the two groups; in particular, the patients who would 
be switched to the EH at IPD appeared to use less ICS or be 
less compliant with their ICS prescriptions and thus sought 
physician services more often.
Most of the devices compared with the EH were pMDIs 
(62.3% of all devices); breath-actuated inhalers (BAIs) 
represented 18.6% of devices, and DPIs other than the EH 
comprised the remaining 19.1% (Table S3). Thus, 81% of 
EH patients switched from a non-DPI to the EH and the 
other 19% switched from another type of DPI to the EH. 
Beclomethasone was the predominant ICS (84.5%) used in 
both groups prior to IPD, but thereafter patients in the EH 
group were fairly equally divided between beclomethasone 
and budesonide. Budesonide, fluticasone, and ciclesonide 
accounted for ,20% of all ICS prescriptions in the OH 
group. In the EH group, 325 patients (33.2%) had a change 
of ICS drug and 286 patients (29.2%) had a decrease in ICS 
dosage at IPD.
Also of note, only 53 patients (2.7%) were also 
 prescribed a long-acting muscarinic antagonist (LAMA): 
31 EH patients (3.2%) and 22 OH patients (2.2%). Of those 
on LAMA  therapy, 45 patients (2.3%) were $40 years of 
age and current or former smokers: 26 EH patients (2.7%) 
and 19 OH patients (1.9%). Thus, the likely incidence of 
COPD instead of, or in addition to, asthma in this study 
population was ,3%.
clinical outcomes
The EH was shown to be non-inferior to the OH for all four 
co-primary clinical outcomes: the differences in proportions 
of patients achieving asthma control had lower 95% CIs 
of .−10% and the differences in proportions of patients 
having no severe exacerbations had upper 95% CIs of ,10% 
(Table 4). After adjusting for baseline confounders, there 
were no significant differences between treatment groups 
for risk domain asthma control or severe exacerbations (both 
definitions) during the outcome year, but patients in the 
EH group were significantly more likely to achieve overall 
asthma control than were those in the OH group (Table 4).
The difference between risk domain and overall asthma 
control lies in SABA usage, specifically the average daily 
prescribed SABA dosage (Table 2). During the outcome year, 
EH patients were significantly less likely than OH patients 
to be in one of the higher SABA usage categories (Table 5). 
Table 4 comparison of co-primary measures of clinical 
effectiveness between the matched treatment groups during the 
outcome year
Outcome EH 
(n=979)
OH 
(n=979)
Difference in 
proportionsa
risk domain asthma control
  controlled, n (%) 707 (72.2%) 715 (73.0%) lower 95% ci:
  Adjusted Orb  
(95% ci)
0.92 (0.74, 1.14) 1.00 −8.7%
exacerbation rate (ATs/ers)
 0, n (%) 881 (90.0%) 892 (91.1%) Upper 95% ci:
 1, n (%) 78 (8.0%) 71 (7.3%) 4.0%
 2+, n (%) 20 (2.0%) 16 (1.6%)
 P=0.318c
  Adjusted rrd  
(95% ci)
1.18 (0.88, 1.59) 1.00
exacerbation rate (clinical)
 0, n (%) 725 (74.1%) 721 (73.6%) Upper 95% ci:
 1, n (%) 172 (17.6%) 169 (17.3%) 4.0%
 2+, n (%) 82 (8.4%) 89 (9.1%)
 P=0.685c
  Adjusted rre  
(95% ci)
0.97 (0.82, 1.15) 1.00
Overall asthma control
 controlled, n (%) 401 (41.0%) 356 (36.4%) lower 95% ci:
  Adjusted Orf  
(95% ci)
1.26 (1.05, 1.52) 1.00 0.4%
Notes: a(eh − Oh), after adjusting for baseline confounders; non-inferiority is shown 
if the lower 95% ci is .−10% for asthma control and the upper 95% ci is ,10% for 
exacerbation rate; badjusted for baseline rhinitis nasal spray and rDAc, ics dose at 
iPD, and age; cconditional logistic regression; dadjusted for cci score and baseline 
lABA use; eadjusted for cci score and baseline exacerbations (clinical); fadjusted for 
baseline rhinitis nasal spray and OAc. easyhaler® (Orion Pharma UK ltd, newbury, 
Berkshire, England). The numbers in bold are statistically significant (P,0.05).
Abbreviations: ATs/ers, American Thoracic society/european respiratory 
Society; CCI, Charlson co-morbidity index; CI, confidence intervals; EH, Easyhaler®; 
ics, inhaled corticosteroid; iPD, index prescription date; lABA, long-acting β2 
receptor agonist; OAc, overall asthma control; Oh, other inhalers; Or, odds ratio; 
rDAc, risk domain asthma control; rr, rate ratio.
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Table 5 comparison of secondary measures of clinical effectiveness 
between the matched treatment groups during the outcome year
Outcome EH 
(n=979)
OH 
(n=979)
P-valuea
Treatment stability (1)
  stable, n (%) 515 (52.6%) 595 (60.8%) –
  Adjusted Orb (95% ci) 0.67 (0.48, 0.92) 1.00
Treatment stability (2)
  stable, n (%) 589 (60.2%) 636 (65.0%)
  Adjusted Orc (95% ci) 0.78 (0.57, 1.06) 1.00
sABA usage (µg/day)
  0, n (%) 143 (14.6%) 134 (13.7%) ,0.001d
  1–100, n (%) 128 (13.1%) 102 (10.4%)
  101–200, n (%) 237 (24.2%) 224 (22.9%)
  201–400, n (%) 260 (26.6%) 268 (27.4%)
  401–800, n (%) 154 (15.7%) 167 (17.1%)
  801+, n (%) 57 (5.8%) 84 (8.6%)
  Adjusted Ore (95% ci) 0.69 (0.59, 0.81) 1.00
controller–reliever ratio
  ,0.5, n (%) 272 (27.8%) 258 (26.4%) 0.430
  $0.5, n (%) 707 (72.2%) 721 (73.6%)
  Mean (sD) 0.6 (0.2) 0.6 (0.2) 0.590
  Median (iQr) 0.6 (0.5, 0.8) 0.6 (0.5, 0.8)
Notes: aconditional logistic regression, except where noted; badjusted for baseline 
rhinitis nasal spray and exacerbations (clinical); cadjusted for baseline rhinitis nasal 
spray and nonasthma-related consultations (categorized); dordinal regression; eodds of 
eh patients being in a higher sABA category compared with Oh patients, adjusted for 
baseline daily sABA dosage. easyhaler® (Orion Pharma UK ltd, newbury, Berkshire, 
England). The numbers in bold are statistically significant (P,0.05).
Abbreviations: CI, confidence intervals; EH, Easyhaler®; iQr, interquartile range; 
Oh, other inhalers; Or, odds ratio; sABA, short-acting β2 receptor agonist; 
sD, standard deviation.
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Figure 2 comparison of average daily sABA dosages between baseline and outcome years for the matched treatment groups.
Notes: Patients in both treatment groups were matched on sABA dosage (categorized as shown) during the baseline year, so the baseline values are identical for eh and Oh 
patients; *Using ordinal regression, the number of patients in each dosage category was significantly different (P,0.001) between eh and Oh groups during the outcome year. 
easyhaler® (Orion Pharma UK ltd, newbury, Berkshire, england).
Abbreviations: eh, easyhaler®; Oh, other inhalers; sABA, short-acting β2 receptor agonist.
During the baseline year, the number of patients on a 
 salbutamol-equivalent SABA dosage of #200 µg/day was 
identical (560 patients, or 57%; Table S2) in both treatment 
groups, SABA dosage being a matching criterion. However, 
while average daily SABA dosages generally increased 
in both treatment groups between baseline and outcome 
years (Figure 2), significantly more EH than OH patients 
remained on a SABA dosage of #200 µg/day (52% and 
47%, respectively; Table 6).
The importance of these differences in SABA usage is fur-
ther reflected in the changes in risk domain and overall asthma 
control status between baseline and outcome years. Whereas 
the number of patients achieving risk domain asthma control 
increased slightly in both groups, from 66%–67% at baseline 
(Table S2) to 72%–73% in the outcome year (Table 4), the 
number of patients achieving overall asthma control dropped 
substantially over the same period. Approximately 60% of 
patients achieved overall asthma control at baseline (Table S2), 
but only 36% (OH) and 41% (EH) achieved overall asthma 
control during the outcome year (P=0.016; Table 4). As SABA 
usage is the single factor that differentiates risk domain and 
overall asthma control, these small differences evidently 
played a significant, albeit indirect, role in the clinical effec-
tiveness of the EH, in that the EH patients used significantly 
less SABA for comparable asthma control.
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The other secondary clinical outcomes are summarized 
in Table 5. Patients in the EH group were significantly less 
likely to achieve treatment stability (definition 1) than those 
in the OH group, but there was no significant difference 
in the odds of achieving treatment stability (definition 2) 
Table 6 Disaggregated components of the clinical effectiveness 
measures between the matched treatment groups during the 
outcome year
Outcome EH 
(n=979)
OH 
(n=979)
P-valuea
courses of oral steroids
 0, n (%) 883 (90.2%) 895 (91.4%) 0.224
 1, n (%) 76 (7.8%) 70 (7.2%)
 2+, n (%) 20 (2.0%) 14 (1.4%)
sABA dosage (µg/day)
 #200, n (%) 508 (51.9%) 460 (47.0%) ,0.001
 .200, n (%) 471 (48.1%) 519 (53.0%)
increase in ics dosage
 Yes, n (%) 125 (12.8%) 76 (7.8%) ,0.001
change in ics drug
 Yes, n (%) 171 (17.5%) 94 (9.6%) ,0.001
change in ics device
 Yes, n (%) 217 (22.2%) 112 (11.4%) ,0.001
Additional therapy
 Any, n (%) 113 (11.5%) 96 (9.8%) 0.210
 BUD-FOr, n (%) 49 (5.0%) 30 (3.1%) 0.034
Notes: aconditional logistic regression. easyhaler® (Orion Pharma UK ltd, newbury, 
Berkshire, England). The numbers in bold are statistically significant (P,0.05).
Abbreviations: BUD-FOR, budesonide-formoterol as fixed-dose combination 
inhaler; eh, easyhaler®; Oh, other inhalers; ics, inhaled corticosteroid; sABA, 
short-acting β2 receptor agonist.
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Figure 3 comparison of average daily ics dosages between baseline and outcome years for the matched treatment groups.
Notes: eh baseline patients were on Oh during their baseline year but were switched to eh at iPD; ics dosages are in BDP-equivalents. in both years, the number 
of patients in each dosage category was significantly different (P,0.001) between treatment groups (conditional logistic regression). easyhaler® (Orion Pharma UK ltd, 
newbury, Berkshire, england).
Abbreviations: BDP, beclomethasone dipropionate; eh, easyhaler®; ics, inhaled corticosteroid; iPD, index prescription date; Oh, other inhalers.
between groups. The key difference between these two 
indices is that a change in ICS drug or device is included 
in the first but not in the second definition of treatment 
 stability. Significantly more EH than OH patients had a 
change in ICS drug or device during the outcome year 
(Table 6), which may explain the difference in outcomes 
for the two treatment stability definitions. Even so, only 
17.5% of EH patients had a change in ICS drug and 22% 
a change in ICS device during the outcome year. Thus, the 
EH evidently was well accepted by patients for the year 
after the switch.
While significantly more EH than OH patients had an 
increase in ICS dosage during their outcome year (12.8% 
and 7.8%, respectively; Table 6), 29% of EH patients had 
undergone a decrease in ICS dosage at IPD. From these data, 
it appears possible that some EH patients may have been inap-
propriately stepped down at IPD; if so, then the increase in 
ICS dosage during the outcome year may simply have been 
a return to an effective ICS dosage in those patients. In both 
treatment groups, ICS dosages generally increased between 
baseline and outcome years (Figure 3), but ICS dosages 
remained significantly higher in the OH than the EH patients 
(Tables S2 and S4).
Just as in the baseline year, EH patients had signifi-
cantly fewer ICS prescriptions and inhalers, lower average 
daily ICS dosages, and less LABA usage than OH patients 
(Table S4). However, there were no longer any significant 
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Discussion
The aim of our study was to critically evaluate the clinical 
and cost effectiveness of switching real-life asthma patients 
from any other type of ICS device to the EH. Our findings 
showed that both aspects of our hypothesis – that such a 
switch would result in a significant reduction in clinical 
effectiveness and thus a significant increase in the costs of 
asthma therapy – were disproven.
By examining a large and diverse population of asthma 
patients – from young children to elderly patients, and 
including smokers, patients with co-morbidities, and those 
with poor treatment compliance – we sought to represent the 
challenges typically faced in primary-care asthma manage-
ment and the circumstances under which a physician might 
switch a patient from one ICS device to another. In an effort 
to include as many EH patients as possible within the limits 
of our study parameters, the EH was compared not only with 
other DPIs but also with pMDIs and BAIs, and across four 
different ICS drugs and a range of ICS dosages that in about 
one-third of patients were substantially different between 
matched cohorts after the switch.
Arguably, more specific associations of clinical impor-
tance may have been identified if our inclusion criteria had 
been more refined. For example, a comparison limited to 
the EH with other DPIs only (no pMDIs or BAIs) may have 
been of value, as might limiting the investigation to one ICS 
drug delivered by EH or OH. However, doing so within our 
present study framework would have reduced group numbers 
considerably; for example, a comparison of the EH with 
other DPIs would have reduced the group numbers to only 
187 patients each.
One of the strengths of our study is that we were able 
to include almost 980 patients in each treatment group, 
and we examined the outcome of the switch against a 
backdrop of real-life asthma management. In addition, our 
study reviewed data for a full 12 months before and after 
the switch. In contrast, most randomized controlled clini-
cal trials typically have very strict selection criteria which 
result in a homogeneous but often poorly representative 
study population, relatively small numbers of patients, and 
relatively short data collection periods.4–6,35,36 By comparing 
various other ICS devices with the EH, and by retrospec-
tively and remotely examining the outcome of the switch, 
we documented the results when primary-care physicians 
switched their asthma patients from another ICS device to 
the EH, regardless of which device the patient was currently 
using. In this respect, our study design put the EH to a very 
challenging test.
differences between treatment groups in controller–reliever 
ratios or primary-care asthma consultations, which sug-
gests better self-management in the EH patients during 
the outcome year compared with the baseline year. The 
incidence of asthma-related hospital outpatient attendance, 
however, remained significantly different between treat-
ment groups and essentially unchanged from baseline. 
No other types of respiratory-related hospital attendance/
admission were significantly different between treatment 
groups (Table S4).
health economic outcomes
There was no significant difference in total asthma-related 
health care costs between treatment groups during the base-
line year (Table 7). There were, however, significant differ-
ences between groups in specific cost components. Asthma 
drug costs were significantly lower in the group who would 
be switched to the EH at IPD, owing in large part to the lower 
number of ICS inhalers and thus ICS costs in these patients. 
However, these lower drug costs evidently were offset by the 
significantly higher number, and thus cost, of primary-care 
asthma consultations and hospital outpatient attendances in 
the EH group. The number and cost of SABA inhalers were 
comparable between treatment groups.
During the outcome year, total asthma-related health 
care costs were significantly lower in the EH group, driven 
largely by lower asthma drug costs (ICS and SABA), as 
asthma-related consultations and costs were no longer sig-
nificantly different from those in the OH group (Table 7). 
Asthma-related hospital outpatient attendance costs remained 
significantly different between groups and were essentially 
unchanged from baseline.
Mean asthma-related health care costs increased from 
baseline to outcome years in both treatment groups, with the 
exception of primary-care asthma consultation costs, which 
decreased in both groups. The changes in costs from baseline 
to outcome years were not significantly different between 
groups for total asthma-related health care costs, asthma drug 
costs, ICS costs, or hospital outpatient attendance costs (Table 
7). However, SABA costs increased significantly more in the 
OH than the EH group (mean difference of £5.5/patient/year) 
and asthma consultation costs decreased significantly more in 
the EH than the OH group (mean difference of £13.5/patient/
year). Thus, switching to the EH in this patient population 
was not more costly than remaining on the same ICS drug, 
dosage, and device, and for some measures it reduced the 
costs of on-going asthma therapy, for equivalent clinical 
effectiveness.
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Table 7 comparison of asthma-related health care costs (£/patient/year) between matched treatment groups for baseline and outcome 
years, including changes (Δ) in costs from baseline to outcome years
Health economic 
measure
Baseline Outcome
EHa OH P-valueb EH OH P-valueb
Total costs (£)
 Mean (sD) 165.2 (179.9) 179.2 (231.2) 0.099 192.1 (223.9) 215.4 (268.5) 0.025
 Median (iQr) 113.8 (68.8, 198.9) 106.7 (63.3, 208.5) 117.4 (66.1, 223.5) 128.9 (69.2, 251.0)
Δ Total costs (£)
 Mean (sD) – – – 26.9 (167.9) 36.2 (158.3) 0.217
 Median (iQr) – – 2.8 (−46.5, 67.2) 15.7 (−28.2, 72.0)
Asthma drug costs (£)
 Mean (sD) 104.6 (159.7) 132.3 (201.0) ,0.001 151.3 (200.5) 179.6 (249.9) 0.003
 Median (iQr) 53.6 (25.2, 117.0) 65.3 (32.7, 152.5) 81.9 (44.9, 171.8) 92.9 (45.2, 207.7)
Δ Asthma drug costs (£)
 Mean (sD) – – – 46.7 (125.2) 47.2 (123.1) 0.929
 Median (iQr) – – 20.0 (−3.9, 62.4) 18.6 (−2.8, 61.7)
ics inhalers (n)
 Mean (sD) 4.3 (3.6) 5.5 (4.8) ,0.001 5.5 (3.8) 6.9 (4.7) ,0.001
 Median (iQr) 3 (2, 6) 4 (2, 7) 4 (3, 7) 6 (3, 9)
ics costs (£)
 Mean (sD) 50.2 (55.9) 59.3 (75.4) ,0.001 65.0 (51.3) 70.8 (73.0) 0.015
 Median (iQr) 30.9 (14.8, 65.9) 38.9 (17.2, 76.2) 50.3 (29.9, 88.6) 49.0 (23.7, 89.6)
Δ ics costs (£)
 Mean (sD) – – – 14.7 (46.1) 11.4 (40.3) 0.094
 Median (iQr) – – 14.0 (−2.9, 34.7) 7.9 (−1.2, 27.5)
sABA inhalers (n) – –
 Mean (sD) 4.8 (6.8) 4.9 (7.2) 0.347 5.1 (6.9) 6.0 (7.8) 0.001
 Median (iQr) 3 (1, 6) 3 (1, 6) 3 (1, 7) 4 (2, 8)
sABA costs (£)
 Mean (sD) 18.7 (34.7) 18.5 (33.6) 0.863 21.0 (43.5) 26.3 (59.2) 0.024
 Median (iQr) 9.2 (2.9, 22.7) 9.0 (2.9, 23.0) 11.8 (3.3, 23.2) 11.5 (4.6, 28.8)
Δ sABA costs (£)
 Mean (sD) – – – 2.3 (25.7) 7.8 (40.5) 0.001
 Median (iQr) – – 0.4 (−3.3, 7.1) 1.5 (−2.3, 8.6)
Asthma consultsc (n)
 Mean (sD) 1.4 (1.2) 1.0 (1.0) ,0.001 0.9 (1.2) 0.9 (1.0) 0.658
 Median (iQr) 1 (1, 2) 1 (0, 1) 1 (0, 1) 1 (0, 1)
consult costs (£)
 Mean (sD) 50.3 (43.8) 36.1 (36.7) ,0.001 31.6 (41.3) 30.8 (36.7) 0.658
 Median (iQr) 36 (36, 72) 36 (0, 36) 36 (0, 36) 36 (0, 36)
Δ consult costs (£)
 Mean (sD) – – – −18.8 (54.3) −5.3 (44.0) ,0.001
 Median (iQr) – – −36 (−36, 0) 0 (−36, 0)
hospitalizationsd (n)
 Mean (sD) 0.06 (0.28) 0.02 (0.19) 0.001 0.05 (0.29) 0.02 (0.19) 0.004
 Median (iQr) 0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0)
hospital costs (£)
 Mean (sD) 7.5 (38.4) 2.3 (26.2) 0.001 7.3 (38.6) 2.8 (25.0) 0.004
 Median (iQr) 0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0)
Δ hospital costs (£)
 Mean (sD) – – – −0.14 (48.3) 0.41 (33.2) 0.767
 Median (iQr) – – 0 (0, 0) 0 (0, 0)
Notes: aThese patients were on Oh during their baseline year but were switched to eh at iPD; bconditional logistic regression; casthma-related primary-care consultations; dasthma-
related hospital outpatient department attendance. easyhaler® (Orion Pharma UK Ltd, Newbury, Berkshire, England). The numbers in bold are statistically significant (P,0.05).
Abbreviations: Δ, change; eh, easyhaler®; ics, inhaled corticosteroid; iPD, index prescription date; iQr, interquartile range; Oh, other inhalers; OPD, outpatient 
department; sABA, short-acting β2 receptor agonist; sD, standard deviation.
By the same token, one of the drawbacks of a study of this 
size and scope is that small baseline differences inevitably 
remained between treatment groups, despite patient matching on 
several clinically relevant variables. One such difference was the 
incidence of potentially important co-morbidities, as expressed 
by the CCI. However, the higher incidence of co-morbidities in 
the EH group may strengthen the case for the EH, although both 
of the exacerbation rate ratios (ATS/ERS and clinical definitions) 
in the outcome year were adjusted for CCI score (Table 4), thus 
reducing the impact of this baseline difference.
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Another difference worth noting is the incidence of 
hospital outpatient attendance during the baseline year, 
which, while low in both groups, was higher in the EH 
group. However, this finding may be noteworthy only for 
its role as a red herring: the rates of asthma-related accident 
and emergency attendance and inpatient admission were 
lower than that of outpatient attendance in both groups and 
were comparable between groups, all of which suggests 
that some patients, particularly in the EH group, may have 
been using the hospital outpatient department as a de facto 
primary-care clinic.
The two matched treatment groups in our study had com-
parable levels of asthma control and exacerbation rates during 
their baseline year, but there were some apparent differences 
in the patterns of medication usage and physician contact 
which suggest that the patients who would be switched to the 
EH were not as compliant with their controller medications 
as those who would remain on the same ICS device for the 
outcome year. Whether or not patient compliance or adher-
ence to their ICS prescription was a factor in the physicians’ 
decision to switch patients to the EH cannot be determined 
with our study design. However, based on published com-
parisons of patient preferences for specific inhalers,2–6,27–29 
it is possible that some patients were switched to the EH 
because they were not satisfied with, or not correctly using, 
their current ICS device.
During the outcome year, the EH compared favorably 
with the other devices in clinical effectiveness, even though 
29% of EH patients underwent a decrease in ICS dosage 
and 33% a change of ICS drug, in addition to the change of 
device, at the index prescription date and 34% were switched 
to the EH without a face-to-face consultation. The importance 
of direct physician contact when switching inhalers cannot be 
overemphasized. In fact, the role of health care professionals 
in ensuring correct inhaler use has been described as critical, 
both in achieving correct inhaler technique initially and in 
maintaining correct inhaler use over time.30
Approximately one in three of the EH patients in our 
study were switched without a face-to-face consultation, and 
possibly even without the patient’s knowledge and consent in 
some cases. Thus, patient training with the new device was 
not always ideal. This seemingly small fact adds weight to 
the effectiveness of the EH when compared with the refer-
ence group: patients who remained on the same ICS device 
they had been using for some time going into the outcome 
year. Whether or not their inhaler technique was optimal, 
the patients in the OH group were at least familiar with their 
device, whereas the patients in the EH group were using the 
EH for the first time at the start of the outcome year. Granted, 
the patients switching to the new device may have been more 
likely to read the product information sheet that came with 
the device and, at least initially, follow the instructions with 
care. However, in-person instruction and demonstration of 
correct inhaler use is documented to be superior to simply 
reading instructions in the patient information leaflet.29,34
All of the patients in both groups had been on ICS therapy 
for months or years prior to the index prescription date and 
so were experienced with general asthma inhaler use. Even 
so, the technical differences among the various ICS devices 
are sufficient that a switch from one type of inhaler to another 
increases the potential for critical handling or inhalation 
errors,22,29,31,34 and switching devices without an accompany-
ing consultation may further compromise asthma control.37,38 
In this light, the EH might be considered to have fared 
remarkably well. Not only was non-inferiority shown for the 
EH compared with the other devices for all four co-primary 
clinical outcome measures, but patients switched to the EH 
were significantly more likely to achieve overall asthma 
control: absence of asthma-related hospital attendance/
admission, GP consultations for LRTI requiring antibiotic 
therapy, and acute courses of oral steroids, and an average 
salbutamol-equivalent SABA dosage of #200 µg/day.
Significantly more EH than OH patients had a change 
in ICS drug or device during the outcome year, which sig-
nificantly decreased the proportion of EH patients achieving 
treatment stability, but only 22% of EH patients had a change 
of ICS device during their outcome year; 78% of EH patients 
continued to use the EH. The positive change in controller–
reliever ratios between baseline and outcome years in the 
EH group further supports a conclusion of satisfaction with 
the new device in the majority of EH patients.
Simply put, when the units of controller and reliever 
medications are equal, the controller–reliever ratio is 0.5; 
if reliever use exceeds controller use, then the ratio drops 
below 0.5. During the baseline year, significantly more 
EH than OH patients had a controller–reliever ratio ,0.5, 
which indicates a lower level of controller use and/or a 
greater reliance on reliever use in the patients who would 
be switched to the EH. However, this difference did not 
persist into the outcome year. While the controller–reliever 
ratios remained essentially unchanged between baseline 
and outcome years in the OH group, the percentage of EH 
patients whose controller–reliever ratio was $0.5 rose from 
64% to 72%, even though SABA usage increased over the 
same period. This finding cannot be fully explained given 
our study design, but coupled with the decrease in primary-
care asthma consultations in the EH group between baseline 
and outcome years, it is consistent with the better patient 
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satisfaction documented for the EH, and thus more regular 
use of controller medications, which ultimately contributes 
to better asthma control.
Both treatment groups showed an increase in average 
daily ICS and SABA usage between baseline and outcome 
years, but the increases were greater in the OH group. 
These changes were reflected in the costs of asthma therapy. 
There were no significant differences in total asthma-related 
health care costs between groups during the baseline year, 
but total costs were significantly lower in the EH than the 
OH group during the outcome year, largely because of 
the greater increase in SABA usage in the OH group and 
the greater decrease in primary-care asthma consultations 
in the EH group between baseline and outcome years. 
These differences, while relatively small in monetary terms, 
may be considered particularly significant when framed in 
human terms: greater overall asthma control and less need 
for primary-care asthma consultations, for comparable or 
lower cost, in the patients switched to the EH.
Conclusion
Switching typical asthma patients from another type of ICS 
device to the EH at the same or lower ICS dosage, even 
in the absence of direct physician contact, was achieved 
without a compromise in clinical effectiveness or increase 
in cost. In fact, patients switched to the EH were signifi-
cantly more likely to achieve overall asthma control and 
had comparable or lower asthma-related health care costs 
in relation to patients who remained on an ICS device other 
than the EH.
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Supplementary materials
Figure S1 (Continued)
Potential confounders examined at (or closest to) the index prescription date (IPD): 
• Age 
• Sex 
• Height 
• Weight 
• Body mass index 
• Ethnicity (if available) 
• Lung function, as indicated by % predicted peak expiratory flowa
• Smoking status 
• Inhaled corticosteroid (ICS) device type 
• ICS drug 
Potential confounders examined in the baseline year: 
• Presence/absence of co-morbid rhinitis (diagnosis ever and/or prescriptions for rhinitis
therapy); where rhinitis is present, use of nasal steroids for its treatment  
• Other important unrelated co-morbidities, expressed using the Charlson co-morbidity index
(CCI)b 
• Presence of gastroesophageal reflux disease (GERD; diagnosis ever and/or prescriptions for 
GERD therapy) 
• Presence of cardiac disease (diagnosis ever and/or prescriptions for cardiac drugs) 
• Number of asthma consultations that did not result in a prescription for an oral steroid 
• Number of hospital outpatient attendances where asthma or other respiratory illness was the
reason for referral   
• Number of hospitalizations for asthma or possibly respiratory-related (a nonspecific
hospitalization code and an asthma/respiratory code within a 1-week window)  
• Number of prescriptions for any antibiotic, where the reason for the prescription was lower
respiratory tract infection  
• Number of prescriptions for the following: 
o Paracetamol 
o Nonsteroidal anti-inflammatory drugs 
o Beta-blockers 
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Figure S1 Potential confounders examined in the initial analysis.
Notes: aThe equations of roberts et al1 were used for patients .18 years of age and the equations of rosenthal et al2 were used for patients 6–18 years of age; bas described 
by Aylin et al.3 
• Number of prescriptions for any respiratory therapy (split by number of prescriptions for each) 
• Number of asthma exacerbations 
• Number of general practice consultations for asthma that did not result in asthma 
 exacerbation treatment 
• Number of short-acting β2 receptor agonist (SABA) prescriptions 
• Average daily SABA dose (total combined dose of re/filled prescriptions, averaged over
  365 days) 
• Average daily ICS dose (total combined dose of re/filled prescriptions, averaged over
  365 days) 
• ICS dosage prescribed at IPD 
• Identification of cases where the patient received inhaled therapy from mixed device types
  (eg, pressurized metered-dose inhaler and dry-powder inhaler)
• Spacer use/prescription 
• Medication-possession ratio ([number of days’ supply of ICS ÷ 365] × 100) 
• First or subsequent (second or more) switch of ICS drug 
• Oral thrush (diagnosis and/or therapy)
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Table S1 Baseline patient characteristics: demographics and co-morbidities
Variable EHa (n=979)b OH (n=979)b P-valuec
Age at iPD (years)
 Mean (sD) 40.5 (25.9) 40.5 (25.9) 0.708
 Median (iQr) 41 (13, 64) 41 (13, 64)
 categorized n/Ad
   Pediatric (6–11 years), n (%) 190 (19.4%) 190 (19.4%)
   Adult (12–60 years), n (%) 498 (50.9%) 498 (50.9%)
   elderly (61–80 years), n (%) 291 (29.7%) 291 (29.7%)
sex n/Ad
 Male, n (%) 439 (44.8%) 439 (44.8%)
 Female, n (%) 540 (55.2%) 540 (55.2%)
smoking status 0.563
  nonsmoker, n (%) 610 (62.3%) 604 (61.7%)
  current smoker, n (%) 127 (13.0%) 138 (14.1%)
 ex-smoker, n (%) 196 (20.0%) 195 (19.9%)
 Unknown, n (%) 46 (4.7%) 42 (4.3%)
% Predicted PeFe
 Mean (sD) 84.3 (22.6) 84.3 (24.9) 0.937
 Median (iQr) 85.5 (68.7, 99.1) 83.9 (66.6, 100.8)
 Patients, n 545 590
Year of iPD
 Mean (sD) 2007.9 (1.7) 2007.9 (1.5) n/Ad
 Median (iQr) 2008 (2007, 2009) 2008 (2007, 2009)
cci score ,0.001
 0 475 (48.5%) 578 (59.0%)
 1–4 401 (41.0%) 313 (32.0%)
 5+ 103 (10.5%) 88 (9.0%)
co-morbidities
 rhinitis,f n (%) 237 (24.2%) 296 (30.2%) 0.003
Notes: aThese patients were on Oh during their baseline year but were switched to eh at iPD; bexcept where noted; cconditional logistic regression; dmatching variable; esee 
Figure S1 for age-specific PEF equations used; frhinitis diagnosis and/or prescription for rhinitis drugs. easyhaler® (Orion Pharma UK ltd, newbury, Berkshire, england).
Abbreviations: cci, charlson co-morbidity index; eh, easyhaler®; iPD, index prescription date; iQr, interquartile range; n/A, not applicable; Oh, other inhalers; PeF, peak 
expiratory flow; SD, standard deviation.
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Table S2 Baseline patient characteristics: disease severity and therapies
Variable EHa (n=979) OH (n=979) P-valueb
risk domain asthma control
 controlled, n (%) 645 (65.9%) 656 (67.0%) 0.534
exacerbation rate (ATs/ers)
 Mean (sD) 0.14 (0.45) 0.14 (0.42) 0.370
 Median (iQr) 0 (0, 0) 0 (0, 0)
 categorized n/Ac
  0, n (%) 865 (88.4%) 865 (88.4%)
  1, n (%) 99 (10.1%) 99 (10.1%)
  2+, n (%) 15 (1.5%) 15 (1.5%)
exacerbation rate (clinical)
 Mean (sD) 0.47 (0.85) 0.47 (0.84) 0.899
 Median (iQr) 0 (0, 1) 0 (0, 1)
 categorized 0.713
  0, n (%) 672 (68.6%) 660 (67.4%)
  1, n (%) 213 (21.8%) 228 (23.3%)
  2+, n (%) 94 (9.6%) 91 (9.3%)
Overall asthma control
 controlled, n (%) 597 (61.0%) 591 (60.4%) 0.655
Acute oral steroid courses
 Mean (sD) 0.13 (0.43) 0.12 (0.39) 0.253
 Median (iQr) 0 (0, 0) 0 (0, 0)
 categorized 0.334
  0, n (%) 878 (89.7%) 884 (90.3%)
  1, n (%) 87 (8.9%) 81 (8.3%)
  2+, n (%) 14 (1.4%) 14 (1.4%)
lrTi consults with a/b script
 Mean (sD) 0.43 (0.86) 0.44 (0.88) 0.870
 Median (iQr) 0 (0, 1) 0 (0, 1)
 categorized 0.796
  0, n (%) 709 (72.4%) 697 (71.2%)
  1+, n (%) 270 (27.6%) 282 (28.8%)
Primary-care consultations
Mean (sD)
 All consults 8.8 (7.1) 8.8 (7.9) 0.995
 Asthma-related 1.4 (1.2) 1.0 (1.0) ,0.001
 Asthma, no oral steroids 1.3 (1.1) 0.9 (1.0) ,0.001
respiratory prescriptions
Mean (sD)
 All scripts 9.1 (9.2) 10.3 (8.9) ,0.001
 Allergy scripts 1.7 (3.6) 2.2 (4.6) 0.005
 sABA scripts 3.7 (4.3) 3.7 (4.4) 0.944
 ics scripts 3.8 (3.2) 4.6 (3.3) ,0.001
 ics inhalers 4.3 (3.6) 5.5 (4.8) ,0.001
Average daily sABA dose (µg)d
 Mean (sD) 270.6 (395.8) 277.9 (420.9) 0.549
 Median (iQr) 164.4 (54.8, 328.8) 164.4 (54.8, 328.8)
 categorized n/Ac
  0, n (%) 165 (16.9%) 165 (16.9%)
  1–200, n (%) 395 (40.3%) 395 (40.3%)
  201–400, n (%) 218 (22.3%) 218 (22.3%)
  401+, n (%) 201 (20.5%) 201 (20.5%)
lABA use
 Yes, n (%) 81 (8.3%) 150 (15.3%) ,0.001
(Continued)
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Table S2 (Continued)
Variable EHa (n=979) OH (n=979) P-valueb
Average daily ics dose (µg)e
 Mean (sD) 309.9 (334.7) 384.3 (440.2) ,0.001
 Median (iQr) 197.3 (109.6, 394.5) 263.0 (109.6, 438.4)
 categorized ,0.001
  1–100, n (%) 192 (19.6%) 148 (15.1%)
  101–200, n (%) 303 (30.9%) 234 (23.9%)
  201–400, n (%) 241 (24.6%) 302 (30.8%)
  401+, n (%) 243 (24.8%) 295 (30.1%)
Asthma-related hospitalizationf
 A&e attendance, n (%) 3 (0.3%) 4 (0.4%) 0.708
 inpatient admission, n (%) 3 (0.3%) 8 (0.8%) 0.148
 inpatient (incl vague), n (%) 25 (2.6%) 20 (2.0%) 0.447
 Outpatient attendance, n (%) 43 (4.4%) 13 (1.3%) ,0.001
controller–reliever ratio
 Mean (sD) 0.6 (0.3) 0.6 (0.2) ,0.001
 Median (iQr) 0.5 (0.4, 0.7) 0.5 (0.5, 08)
 categorized ,0.001
  ,0.5, n (%) 349 (35.6%) 262 (26.8%)
  $0.5, n (%) 630 (64.4%) 717 (73.2%)
Notes: aThese patients were on Oh during their baseline year but were switched to eh at iPD; bconditional logistic regression; cmatching variable; dsalbutamol-equivalent 
dosages; eBDP-equivalent dosages; average daily ics dosage = total combined dose of re/filled prescriptions, averaged over 365 days; fany asthma- or respiratory-related 
hospital attendance/admission during the baseline year. easyhaler® (Orion Pharma UK Ltd, Newbury, Berkshire, England). The numbers in bold are statistically significant 
(P,0.05).
Abbreviations: a/b, antibiotic; A&e, Accident and emergency department; ATs/ers, American Thoracic society/european respiratory society; BDP, beclomethasone 
dipropionate; eh, easyhaler®; ics, inhaled corticosteroid; iPD, index prescription date; iQr, interquartile range; lABA, long-acting β2 receptor agonist; lrTi, lower 
respiratory tract infection; n/A, not applicable; Oh, other inhalers; sABA, short-acting β2 receptor agonist; sD, standard deviation.
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Table S3 Baseline patient characteristics: ics drugs, dosages, and devices
Variable EHa (n=979) OH (n=979) P-valueb
ics drug prior to iPD n/Ac
 Beclomethasone, n (%) 827 (84.5%) 827 (84.5%)
 Fluticasone, n (%) 22 (2.2%) 22 (2.2%)
 Budesonide, n (%) 129 (13.2%) 129 (13.2%)
 ciclesonide, n (%) 1 (0.1%) 1 (0.1%)
ics drug at iPD ,0.001
 Beclomethasone, n (%) 525 (53.6%) 827 (84.5%)
 Fluticasone, n (%) 0 (0.0%) 22 (2.2%)
 Budesonide, n (%) 454 (46.4%) 129 (13.2%)
 ciclesonide, n (%) 0 (0.0%) 1 (0.1%)
ics dosage prior to iPD (µg)d
 Mean (sD) 467.0 (238.8) 467.0 (238.8) n/Ac
 Median (iQr) 400 (400, 400) 400 (400, 400)
 categorized n/Ac
  1–200, n (%) 188 (19.2%) 188 (19.2%)
  201–400, n (%) 561 (57.3%) 561 (57.3%)
  401+, n (%) 230 (23.5%) 230 (23.5%)
ics dosage at iPD (µg)d
 Mean (sD) 368.9 (162.2) 466.2 (243.0) ,0.001
 Median (iQr) 400 (200, 400) 400 (400, 400)
 categorized ,0.001
  1–200, n (%) 310 (31.7%) 189 (19.3%)
  201–400, n (%) 592 (60.5%) 564 (57.6%)
  401+, n (%) 77 (7.9%) 226 (23.1%)
ics device prior to iPD n/Ac
 MDi, n (%) 610 (62.3%) 610 (62.3%)
 BAi, n (%) 182 (18.6%) 182 (18.6%)
 DPi, n (%) 187 (19.1%) 187 (19.1%)
ics device at iPD 0.984
 MDi, n (%) 0 (0.0%) 610 (62.3%)
 BAi, n (%) 0 (0.0%) 182 (18.6%)
 DPi, n (%) 979 (100.0%) 187 (19.1%)
Notes: aThese patients were on Oh during their baseline year but were switched to eh at iPD; bconditional logistic regression; cmatching variable; dBDP-equivalents. 
easyhaler® (Orion Pharma UK Ltd, Newbury, Berkshire, England). The numbers in bold are statistically significant (P,0.05).
Abbreviations: BAi, breath-actuated inhaler; BDP, beclomethasone dipropionate; DPi, dry-powder inhaler; eh, easyhaler®; ics, inhaled corticosteroid; iPD, index 
prescription date; iQr, interquartile range; MDi, metered-dose inhaler; n/A, not applicable; Oh, other inhalers; sD, standard deviation.
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Table S4 Patient characteristics during the outcome year: disease severity and therapies
Variable EHa (n=979) OH (n=979) P-valueb
risk domain asthma control
 controlled, n (%) 707 (72.2%) 715 (73.0%) 0.677
exacerbation rate (ATs/ers)
 Mean (sD) 0.13 (0.45) 0.11 (0.42) 0.337
 Median (iQr) 0 (0, 0) 0 (0, 0)
 categorized 0.318
  0, n (%) 881 (90.0%) 892 (91.1%)
  1, n (%) 78 (8.0%) 71 (7.3%)
  2+, n (%) 20 (2.0%) 16 (1.6%)
exacerbation rate (clinical)
 Mean (sD) 0.4 (0.9) 0.4 (0.9) 0.866
 Median (iQr) 0 (0, 1) 0 (0, 1)
 categorized 0.685
  0, n (%) 725 (74.1%) 721 (73.6%)
  1, n (%) 172 (17.6%) 169 (17.3%)
  2+, n (%) 82 (8.4%) 89 (9.1%)
Overall asthma control
 controlled, n (%) 401 (41.0%) 356 (36.4%) 0.016
Acute oral steroid courses
 Mean (sD) 0.13 (0.44) 0.11 (0.40) 0.216
 Median (iQr) 0 (0, 0) 0 (0, 0)
 categorized 0.224
  0, n (%) 883 (90.2%) 895 (91.4%)
  1, n (%) 76 (7.8%) 70 (7.2%)
  2+, n (%) 20 (2.0%) 14 (1.4%)
lrTi consults with a/b script
 Mean (sD) 0.39 (0.87) 0.39 (0.86) 0.978
 Median (iQr) 0 (0, 0) 0 (0, 0)
 categorized 0.745
  0, n (%) 742 (75.8%) 748 (76.4%)
  1+, n (%) 237 (24.2%) 231 (23.6%)
Primary-care consultations
Mean (sD)
 All consults 8.8 (8.1) 8.9 (8.7) 0.659
 Asthma-related 0.9 (1.1) 0.9 (1.0) 0.658
 Asthma, no oral steroids 0.8 (1.1) 0.8 (0.9) 0.784
respiratory prescriptions
Mean (sD)
 All scripts 10.8 (9.9) 12.6 (10.1) ,0.001
 Allergy scripts 1.9 (4.4) 2.5 (4.7) 0.006
 sABA scripts 4.1 (4.5) 4.5 (4.8) 0.012
 ics scripts 4.8 (3.4) 5.8 (3.6) ,0.001
 ics inhalers 5.5 (3.8) 6.9 (4.7) ,0.001
Average daily sABA dose (µg)c
 Mean (sD) 281.3 (390.9) 332.7 (441.9) ,0.001
 Median (iQr) 164.4 (54.8, 383.6) 219.2 (109.6, 438.4)
 categorized ,0.001
  0, n (%) 143 (14.6%) 134 (13.7%)
  1–200, n (%) 365 (37.3%) 326 (33.3%)
  201–400, n (%) 260 (26.6%) 268 (27.4%)
  401+, n (%) 211 (21.5%) 251 (25.6%)
lABA use
 Yes, n (%) 101 (10.3%) 160 (16.3%) ,0.001
(Continued)
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Table S4 (Continued)
Variable EHa (n=979) OH (n=979) P-valueb
Average daily ics dose (µg)d
 Mean (sD) 355.1 (304.8) 493.6 (462.1) ,0.001
 Median (iQr) 274 (164, 438) 329 (192, 658)
 categorized ,0.001
  1–200, n (%) 327 (33.4%) 249 (25.4%)
  201–400, n (%) 375 (38.3%) 315 (32.2%)
  401–800, n (%) 202 (20.6%) 235 (24.0%)
  801+, n (%) 75 (7.7%) 180 (18.4%)
Asthma-related hospitalizatione
 A&e attendance, n (%) 2 (0.2%) 5 (0.5%) 0.274
 inpatient admission, n (%) 2 (0.2%) 2 (0.2%) 1.000
 inpatient (incl vague), n (%) 16 (1.6%) 12 (1.2%) 0.451
 Outpatient attendance, n (%) 41 (4.2%) 14 (1.4%) ,0.001
controller–reliever ratio
 Mean (sD) 0.6 (0.2) 0.6 (0.2) 0.590
 Median (iQr) 0.5 (0.5, 0.8) 0.5 (0.5, 08)
 categorized 0.430
  ,0.5, n (%) 272 (27.8%) 258 (26.4%)
  $0.5, n (%) 707 (72.2%) 721 (73.6%)
Notes: aThese patients were on Oh during their baseline year but were switched to eh at iPD; bconditional logistic regression; csalbutamol-equivalent dosages; 
dBDP-equivalent dosages; eany asthma- or respiratory-related hospital attendance/admission during the baseline year. easyhaler® (Orion Pharma UK ltd, newbury, Berkshire, 
England). The numbers in bold are statistically significant (P,0.05).
Abbreviations: a/b, antibiotic; A&e, Accident and emergency department; ATs/ers, American Thoracic society/european respiratory society; BDP, beclomethasone 
dipropionate; eh, easyhaler®; ics, inhaled corticosteroid; iPD, index prescription date; iQr, interquartile range; lABA, long-acting β2 receptor agonist; lrTi, lower 
respiratory tract infection; n/A, not applicable; Oh, other inhalers; sABA, short-acting β2 receptor agonist; sD, standard deviation.
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